DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

Notice of Grant Award to Waimanalo Health Center for a Project Entitled, "The Hauula Community Diabetes Screening Program"

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS. **ACTION:** Notice of grant award.

SUMMARY: The Centers for Medicare & Medicaid Services has awarded a grant entitled "The Hauula Community Diabetes Screening Program" to the Waimanalo Health Center, 41–1347 Kalanianaole Highway, Waimanalo, Hawaii 96795, in response to an unsolicited application.

Purpose: The Waimanalo Health Center proposes to provide diabetes and related risk factor health screening as well as relevant health educational and behavioral intervention services to the geographically isolated, mostly-Samoan community of Hauula (pop. 3,651) on Oahu. Services will be targeted to its Samoan citizens but open to all residents of Hauula regardless of their ethnicity.

Total Amount of Award: \$987,317. *Project Period:* September 30, 2004, through March 30, 2006.

Sole Source Justification: This unsolicited proposal is responsive to the Senate Appropriations Committee's commitment to the concept of a demonstration project for American Samoans in Hawaii that will integrate social services, to include traditional health, preventive health, prevention and disease management, and address the health disparities among Native Hawaiians and other minority populations by utilizing the expertise of the Waimanalo Health Čenter. The grant will provide diabetes and related risk factor health screening, as well as relevant health educational and behavioral intervention services, to the geographically isolated, mostly-Samoan community of Hauula on Oahu, but project services will be made available to all Hauula residents regardless of their ethnicity. These services will help improve the administration and effectiveness of programs carried on or assisted under the Social Security Act and programs related thereto. The appropriation to the CMS research budget was increased to include funding to carry out this project.

FOR FURTHER INFORMATION CONTACT: Mary Kapp, Project Officer, Division of Beneficiary Research; Research and Evaluation Group; Office of Research Development, and Information, C3–19– 07, 7500 Security Boulevard, Baltimore, MD 21244, (410) 786–0360, or Judith Norris, Grants Officer, OICS/AGG/CMS, C2–21–15, 7500 Security Boulevard, Baltimore, MD 21244, (410) 786–5130.

Authority: (Catalog of Federal Domestic Assistance Program No. 93.779 (CMS) Research, Demonstrations and Evaluations) Section 1110 of the Social Security Act.

Dated: October 29, 2004.

Mark B. McClellan,

Administrator, Centers for Medicare & Medicaid Services.

[FR Doc. 04–24765 Filed 11–4–04; 8:45 am] BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS. **ACTION:** Notice.

SUMMARY: The Department of Health and Human Services (HHS) notifies Federal agencies of the laboratories currently certified to meet the standards of Subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the **Federal Register** on April 11, 1988 (53 FR 11970), and subsequently revised in the **Federal Register** on June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on April 13, 2004 (69 FR 19644).

A notice listing all currently certified laboratories is published in the **Federal Register** during the first week of each month. If any laboratory's certification is suspended or revoked, the laboratory will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any laboratory has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at *http://workplace.samhsa.gov* and *http://www.drugfreeworkplace.gov*. **FOR FURTHER INFORMATION CONTACT:** Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, SAMHSA/CSAP, Room 2–1035, 1 Choke Cherry Road, Rockville, Maryland 20857; (240) 276–2600 (voice), (240) 276–2610 (fax).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100-71. Subpart C of the Mandatory Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards that laboratories must meet in order to conduct drug and specimen validity tests on urine specimens for Federal agencies. To become certified, an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A laboratory must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Mandatory Guidelines dated April 13, 2004 (69 FR 19644), the following laboratories meet the minimum standards to conduct drug and specimen validity tests on urine specimens:

- ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, (414) 328–7840/ (800) 877–7016, (Formerly: Bayshore Clinical Laboratory).
- ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, (585) 429– 2264.
- Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, (901) 794–5770/(888) 290–1150.
- Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 37210, (615) 255–2400.
- Baptist Medical Center—Toxicology Laboratory, 9601 I–630, Exit 7, Little Rock, AR 72205–7299, (501) 202–2783, (Formerly: Forensic Toxicology Laboratory Baptist Medical Center).
- Clinical Reference Lab, 8433 Quivira Rd.,
- Lenexa, KS 66215–2802, (800) 445–6917.
- Diagnostic Services Inc., dba DSI, 12700 Westlinks Dr., Fort Myers, FL 33913, (239) 561–8200/(800) 735–5416.
- Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, (229) 671–2281.
- DrugProof, Division of Dynacare/Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, (206) 386–2661/(800) 898– 0180, (Formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.).
- DrugScan, Inc., P.O. Box 2969, 1119 Mearns Rd., Warminster, PA 18974, (215) 674– 9310.